Efficacy and pharmacodynamics of gemifloxacin versus levofloxacin in guinea pig pneumococcal pneumonia induced by strains with decreased ciprofloxacin susceptibility

International Journal of Antimicrobial Agents

Volumn 21, Issue 6, 2003, Pages 568-573

  Garcia Olmos M ^a   Parra, A ^a   Garcia Calvo G ^a   Ponte, C ^a   Gimenez M J ^b   Aguilar, L ^b   Soriano, F ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b GLAXOSMITHKLINE   (Spain)

Author keywords

Ciprofloxacin; Experimental pneumonia; Gemifloxacin; Levofloxacin; Streptococcus pneumoniae

Indexed keywords

CIPROFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM DETECTION; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; FEMALE; GUINEA PIG; LOBAR PNEUMONIA; LUNG; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PNEUMONIAE;

EID: 0037844817     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(03)00059-1     Document Type: Article

References (23)

1. Chen D.K., McGeer A., de Azavedo J.C., Low D.E. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network. N. Engl. J. Med. 341:1999;233-239.
2. Granizo J.J., Aguilar L., Casal J., Garcia-Rey C., Dal-Re R., Baquero F. Streptococcus pneumoniae resistance to erythromycin and penicillin in relation to macrolide and beta-lactam consumption in Spain (1979-1997). J. Antimicrob. Chemother. 46:2000;767-773.
3. Balcabao I.P., Aguilar L., Martin M., Garcia Y., Dal-Re R., Prieto J. Activities against Streptococcus pneumoniae of amoxicillin and cefotaxime at physiological concentrations: in vitro pharmacodynamic simulation. Antimicrob. Agents Chemother. 40:1996;2904-2906.
4. Fenoll A., Casal J., Giménez M.J., Jado I., Aguilar L. Short-term bactericidal activity of amoxicillin and cefotaxime against penicillin-susceptible and -resistant pneumococcal strains: an in vitro pharmacodynamic simulation. J. Chemother. 12:2000;124-128.
5. Fuentes F., Giménez M.J., Marco F., Alou L., Aguilar L., Prieto J. In vitro susceptibility to gemifloxacin and trovafloxacin of Streptococcus pneumoniae strains exhibiting decreased susceptibility to ciprofloxacin. Eur. J. Clin. Microbiol. Infect. Dis. 19:2000;137-139.
6. Joyanes P., Pascual A., Giménez M.J., Garcia I., Aguilar L., Perea E. Differences between two new quinolones (gemifloxacin and trovafloxacin) and ciprofloxacin in their concentration-dependent killing of Streptococcus pneumoniae. Chemotherapy. 47:2001;409-414.
7. Prieto J., Aguilar L., Fuentes F., et al. Influence of diminished susceptibility of Streptococcus pneumoniae to ciprofloxacin on the serum bactericidal activity of gemifloxacin and trovafloxacin after a single dose in healthy volunteers. Int. J. Antimicrob. Agents. 18:2001;231-238.
8. Kohler T., Pechere J.C. Bacterial resistance to quinolones. Andriole V.T. The Quinolones. 2000;Academic Press, London.
9. Cenjor C., Ponte C., Parra A., et al. In vivo efficacies of amoxicillin and cefuroxime against penicillin-resistant Streptococcus pneumoniae in a gerbil model of acute otitis media. Antimicrob. Agents Chemother. 42:1998;1361-1364.
10. Soriano F., Parra A., Cenjor C., et al. Role of Streptococcus pneumoniae and Haemophilus influenzae in the development of acute otitis media and otitis media with effusion in a gerbil model. J. Infect. Dis. 181:2000;646-652.
11. Soriano F., Ponte C., Nieto E., Parra A. Correlation of in-vitro activity and pharmacokinetic parameters with in-vivo effect of amoxicillin, co-amoxiclav and cefotaxime in a murine model of pneumococcal pneumonia. J. Antimicrob. Chemother. 38:1996;227-236.
12. Frimodt-Moller N. Correlation of in vitro activity and pharmacokinetic parameters with effect in vivo for antibiotics: observations from experimental pneumococcus infection. Dan. Med. Bull. 35:1988;422-437.
13. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents, Document M26-T. NCCLS, Vilanova, PA, 1992.
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing, Eleventh Informational Supplement M100-S11. NCCLS, Vilanova, PA, 2001.
15. Ponte C., Parra A., Nieto E., Soriano F. Development of experimental pneumonia by infection with penicillin-insensitive Streptococcus pneumoniae in guinea pigs and their treatment with amoxicillin, cefotaxime, and meropenem. Antimicrob. Agents Chemother. 40:1996;2698-2702.
16. Karabalut N., Drusano G.L. Pharmacokinetics of the quinolone antimicrobial agents. Hooper D.C., Wolfson J.S. Quinolone Antimicrobial Agents. 1993;American Society for Microbiology, Washington, DC.
17. Kim M., Nightingale C.H. Pharmacokinetics and pharmacodynamics of the fluoroquinolones. Andriole V.T. The Quinolones. 2000;Academic Press, London.
18. García-Calvo G., Parra A., Aguilar L., et al. Ex vivo urine antibacterial properties of gemifloxacin and trovafloxacin: a phase I study. Antimicrob. Agents Chemother. 45:2001;1876-1978.
19. Garcia-Rey C., Aguilar L., Baquero F. Influences of different factors on prevalence of ciprofloxacin resistance in Streptococcus pneumoniae in Spain. Antimicrob. Agents Chemother. 44:2000;3481-3482.
20. Tateda K., Takashima K., Miyazaki H., Matsumoto T., Hatori T., Yamaguchi K. Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model. Antimicrob. Agents Chemother. 40:1996;1520-1525.
21. Woodnutt G., Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 43:1999;29-34.
22. Andes D, Craig WA. In vivo pharmacodynamic activity of gemifloxacin against multiple bacterial pathogens. In: Program and Abstracts, 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999 [Abstract No. 27].
23. Preston S.L., Drusano G.L., Berman A.L., et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. J. Am. Med. Assoc. 279:1998;125-129.